(주)모아바이오

Antibody System

[Antibodysystem] Urelumab ELISA Kit

Cat-No. KDG11001

AntibodySystem는 Primary Antibody Biosimilar - Research Grade

제품을 전문적으로 생산하는 20년의 경험이 있는 High Quality 제조사입니다.

제품 설명

Urelumab ELISA Kit

제품 번호

KDG11001

제품 특징

Catalog No.

KDG11001

Description

PRINCIPLE OF THE ASSAY This assay employs the quantitative indirect enzyme immunoassay technique. Recombinant Human CD137 has been pre-coated onto a microplate. Standards or samples are pipetted into the wells and any Urelumab present is bound by the immobilized protein. After washing away any unbound substances, a biotin-labeled Mouse Anti-Human IgG antibody is added to the wells. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of Urelumab bound in the initial step. The color development is stopped and the intensity of the color is measured.

Applications

Used for the quantitative determination of Urelumab concentration in serum and plasma.

Detection method

Colorimetric

Sample type

Plasma, Serum

Assay type

Quantitative

Range

31.25 - 2,000 ng/mL

Sensitivity

18.73 ng/mL

Precision

PRECISION

Intra-Assay Precision (Precision within an assay): <10%

Three samples of known concentration were tested sixteen times on one plate to assess intra-assay precision.

Inter-Assay Precision (Precision between assays): <15%

Three samples of known concentration were tested in twenty four separate assays to assess inter-assay precision.

	Intra-Assay Precision			Inter-Assay Precision
Sample	1	2	3	1	2	3
n	16	16	16	24	24	24
Mean (ng/mL)	1043.6	246.7	55.1	1054.4	255.2	71.6
Standard deviation	52.5	15.7	2.2	45.4	11.8	8.2
CV (%)	5.0	6.4	4.0	4.3	4.6	11.5

Recovery

80-120%

Shipping

2-8 ℃

Stability and Storage

When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%. For unopened kits, if you want to prolong the storage time, please store the Standard, Detection A, Detection B and Microplate at - 20℃, the rest reagents should be store at 4℃.

Alternative Names

BMS-663513, CAS: 934823-49-1

Background

Urelumab is a fully humanized agonistic monoclonal antibody targeting the CD137 receptor with potential immunostimulatory and antineoplastic activities. Urelumab specifically binds to and activates CD137-expressing immune cells, stimulating an immune response, in particular a cytotoxic T cell response, against tumor cells. Urelumab has been used in trials studying the treatment of Leukemia, Multiple Myeloma, Malignant Tumors, and Cancer-Solid Tumors and B-Cell Non-Hodgkin's Lymphoma. The antibody product was developed using Medarex's UltiMAb(R) technology and was the first UltiMAb-derived antibody in clinical development by Bristol-Myers Squibb under the December 2003 agreement with Medarex. In December 2008, enrolment was stopped for all urelumab studies following the occurrence of two hepatotoxicity-related deaths. Several years later, the clinical study on Urelumab was restarted. At present, the approval of the monoclonal antibody has not been disclosed in the relevant drug approval agency.

Data Image

Experiment Example
CALCULATION OF RESULTS
Average the duplicate readings for each standard and sample. Construct a standard curve by plotting the mean absorbance for each standard on the Y-axis against the concentration on the X-axis and draw a best fit curve through the points on the graph. The data may be linearized by plotting the log of the Urelumab concentrations versus the log of the O.D. and the best fit line can be determined by regression analysis. This procedure will produce an adequate but less precise fit of the data.
If samples have been diluted, the concentration read from the standard curve must be multiplied by the dilution factor.